TSVC — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases.
BiotechHealthtechRedwood City, US
Judith Shizuru(Director)Herb Cross(Executive Officer)Jeet Mahal(Executive Officer, Director)Patrick Crutcher(Director)Svetlana Lucas(Director)Wenru Song(Executive Officer)
Co-investorsAvego BioScience CapitalAbingworthIkarian Capital
DexMate develops physical AI technology, providing products intended to support the building of embodied AI and robotics systems.
AI & Machine LearningHardwareRoboticsSanta Clara, US
Yuzhe Qin(Executive Officer, Director)Tao Chen(Executive Officer, Director)Chongyang Wang(Executive Officer, Director)
Co-investorsLG Technology Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.